Q & M Dental Group (Singapore) Valuation
Is QC7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of QC7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: QC7 (SGD0.29) is trading below our estimate of fair value (SGD0.72)
Significantly Below Fair Value: QC7 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for QC7?
Key metric: As QC7 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is QC7's PE Ratio? | |
|---|---|
| PE Ratio | 16.9x |
| Earnings | S$15.98m |
| Market Cap | S$270.44m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 12.5x |
| PEG Ratio | 3x |
Price to Earnings Ratio vs Peers
How does QC7's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18.4x | ||
5NG Healthway Medical | 24.5x | n/a | S$213.2m |
5G3 TalkMed Group | 20.6x | n/a | S$584.2m |
1B1 HC Surgical Specialists | 11x | n/a | S$42.3m |
OTX Medinex | 17.6x | n/a | S$27.2m |
QC7 Q & M Dental Group (Singapore) | 16.9x | 5.6% | S$270.4m |
Price-To-Earnings vs Peers: QC7 is expensive based on its Price-To-Earnings Ratio (16.9x) compared to the peer average (16.4x).
Price to Earnings Ratio vs Industry
How does QC7's PE Ratio compare vs other companies in the Asian Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: QC7 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the Asian Healthcare industry average (20.8x).
Price to Earnings Ratio vs Fair Ratio
What is QC7's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.9x |
| Fair PE Ratio | 23x |
Price-To-Earnings vs Fair Ratio: QC7 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the estimated Fair Price-To-Earnings Ratio (23x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | S$0.28 | S$0.35 +21.9% | 6.6% | S$0.37 | S$0.31 | n/a | 4 |
| Nov ’25 | S$0.30 | S$0.35 +13.9% | 6.6% | S$0.37 | S$0.31 | n/a | 4 |
| Oct ’25 | S$0.28 | S$0.35 +24.1% | 6.6% | S$0.37 | S$0.31 | n/a | 4 |
| Sep ’25 | S$0.28 | S$0.35 +26.4% | 6.6% | S$0.37 | S$0.31 | n/a | 4 |
| Aug ’25 | S$0.28 | S$0.35 +24.1% | 6.6% | S$0.37 | S$0.31 | n/a | 4 |
| Jul ’25 | S$0.24 | S$0.35 +44.8% | 6.6% | S$0.37 | S$0.31 | n/a | 4 |
| Jun ’25 | S$0.23 | S$0.35 +47.9% | 6.6% | S$0.37 | S$0.31 | n/a | 4 |
| May ’25 | S$0.24 | S$0.35 +41.5% | 7.6% | S$0.37 | S$0.31 | n/a | 3 |
| Apr ’25 | S$0.24 | S$0.35 +41.5% | 7.6% | S$0.37 | S$0.31 | n/a | 3 |
| Mar ’25 | S$0.24 | S$0.33 +37.5% | 6.1% | S$0.35 | S$0.31 | n/a | 2 |
| Feb ’25 | S$0.24 | S$0.33 +34.7% | 6.1% | S$0.35 | S$0.31 | n/a | 2 |
| Jan ’25 | S$0.26 | S$0.33 +29.4% | 6.1% | S$0.35 | S$0.31 | n/a | 2 |
| Dec ’24 | S$0.23 | S$0.33 +43.5% | 6.1% | S$0.35 | S$0.31 | n/a | 2 |
| Nov ’24 | S$0.21 | S$0.33 +53.5% | 6.1% | S$0.35 | S$0.31 | S$0.30 | 2 |
| Oct ’24 | S$0.27 | S$0.34 +28.3% | 6.4% | S$0.36 | S$0.31 | S$0.28 | 3 |
| Sep ’24 | S$0.28 | S$0.34 +21.4% | 6.4% | S$0.36 | S$0.31 | S$0.28 | 3 |
| Aug ’24 | S$0.32 | S$0.38 +21.7% | 6.8% | S$0.42 | S$0.36 | S$0.28 | 3 |
| Jul ’24 | S$0.29 | S$0.38 +32.2% | 6.8% | S$0.42 | S$0.36 | S$0.24 | 3 |
| Jun ’24 | S$0.28 | S$0.42 +49.1% | 15.2% | S$0.52 | S$0.36 | S$0.23 | 4 |
| May ’24 | S$0.32 | S$0.42 +30.5% | 15.2% | S$0.52 | S$0.36 | S$0.24 | 4 |
| Apr ’24 | S$0.32 | S$0.42 +30.5% | 15.2% | S$0.52 | S$0.36 | S$0.24 | 4 |
| Mar ’24 | S$0.33 | S$0.44 +34.1% | 11.1% | S$0.52 | S$0.40 | S$0.24 | 4 |
| Feb ’24 | S$0.36 | S$0.44 +22.9% | 11.1% | S$0.52 | S$0.40 | S$0.24 | 4 |
| Jan ’24 | S$0.32 | S$0.44 +40.5% | 11.1% | S$0.52 | S$0.40 | S$0.26 | 4 |
| Dec ’23 | S$0.33 | S$0.44 +34.1% | 11.1% | S$0.52 | S$0.40 | S$0.23 | 4 |
| Nov ’23 | S$0.34 | S$0.52 +55.2% | 23.0% | S$0.71 | S$0.40 | S$0.21 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Yunnan Energy International
HK$209.3m
An investment holding company, distributes analytical and laboratory instruments, and life science equipment in the People’s Republic of China, Hong Kong, Macau, Oceania, Asia, and internationally.
T43
HK$0.075
7D
0%
1Y
n/a
IHH Healthcare Berhad
RM 63.4b
An investment holding company, provides healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Turkey, Europe, and internationally.
Q0F
RM 2.15
7D
-1.4%
1Y
29.5%
Econ Healthcare (Asia)
S$58.5m
An investment holding company, engages in the operation of medicare centers and nursing homes for eldercare in Singapore, Malaysia, and China.
EHG
S$0.22
7D
4.8%
1Y
10.0%